Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients

被引:44
作者
Penson, MG
Fricker, FJ
Thompson, JR
Harker, K
Williams, BJ
Kahler, DA
Schowengerdt, KO
机构
[1] Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA
[2] Univ Florida, Coll Med, Dept Stat, Gainesville, FL 32610 USA
[3] Univ Florida, Shands Transplant Ctr, Gainesville, FL USA
[4] Univ Florida, Dept Pharm Serv, Gainesville, FL USA
关键词
D O I
10.1016/S1053-2498(01)00251-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Hyperlipidemia is common after cardiac transplantation and it is a risk factor for post-transplantation coronary artery disease. Immunosuppression with corticosteroids and cyclosporine has been associated with hyperlipidemia. Pravastatin, a HMG-CoA reductase inhibitor, has been shown to be effective and safe for cholesterol reduction in adult heart transplant recipients. To our knowledge the safety and efficacy of pravastatin therapy in pediatric and adolescent heart transplant populations have not been previously analyzed. Therefore, we evaluated lipid profiles, liver transaminases, rejection data, and possible side effects in pediatric and adolescent cardiac transplant recipients treated with pravastatin. Methods: The study group consisted of 40 cardiac transplant recipients 10 to 21 years old (mean age 16.9 years). Twenty-two patients received pravastatin in addition to an immunosuppressive regimen of either cyclosporine or tacrolimus, azathioprine or mycophenolate mofetil, and prednisone. Serial determinations of total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein, and triglycerides were available for all pravastatin-treated patients. Pre-treatment lipid values and hepatic transaminases were compared with those measured after therapy with pravastatin. Comparison of pravastatin-induced lipid reduction between groups treated with cyclosporine vs tacrolimus was also made. Results: Patients receiving pravastatin experienced a mean 32 mg/dl decrease in TC (p < 0.005) and a mean 31 mg/dl decrease in LDL (p < 0.005), regardless of their immunosuppressive regimen. No statistical differences occurred in the magnitude of mean lipid reduction induced by pravastatin between the groups treated with cyclosporine vs tacrolimus. No significant changes in hepatic transaminase levels were noted, and no clinical evidence of pravastatin-induced myositis occurred in any subjects.
引用
收藏
页码:611 / 618
页数:8
相关论文
共 25 条
  • [11] LIPOPROTEIN(A) AND APOLIPOPROTEIN CHANGES AFTER CARDIAC TRANSPLANTATION
    FARMER, JA
    BALLANTYNE, CM
    FRAZIER, OH
    RADOVANCEVIC, B
    PAYTONROSS, C
    PATSCH, W
    MORRISETT, JD
    GOTTO, AM
    YOUNG, JB
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (04) : 926 - 930
  • [12] HESS ML, 1983, CIRCULATION, V68, P94
  • [13] Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease
    Hino, I
    Akama, H
    Furuya, T
    Ueda, H
    Taniguchi, A
    Hara, M
    Kashiwazaki, S
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (07): : 1259 - 1260
  • [14] Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation
    Keogh, A
    Macdonald, P
    Kaan, A
    Aboyoun, C
    Spratt, P
    Mundy, J
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2000, 19 (06) : 529 - 537
  • [15] KEOGH A, 1988, J HEART TRANSPLANT, V7, P171
  • [16] Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia
    Knipscheer, HC
    Boelen, CCA
    Kastelein, JJP
    VanDiermen, DE
    Groenemeijer, BE
    VanDenEnde, A
    Buller, HR
    Bakker, HD
    [J]. PEDIATRIC RESEARCH, 1996, 39 (05) : 867 - 871
  • [17] EFFECT OF PRAVASTATIN ON OUTCOMES AFTER CARDIAC TRANSPLANTATION
    KOBASHIGAWA, JA
    KATZNELSON, S
    LAKS, H
    JOHNSON, JA
    YEATMAN, L
    WANG, XM
    CHIA, D
    TERASAKI, PI
    SABAD, A
    COGERT, GA
    TROSIAN, K
    HAMILTON, MA
    MORIGUCHI, JD
    KAWATA, N
    HAGE, A
    DRINKWATER, DC
    STEVENSON, LW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (10) : 621 - 627
  • [18] KORNBRUST DJ, 1989, J PHARMACOL EXP THER, V248, P498
  • [19] Maggard MA, 1998, TRANSPLANTATION, V65, P149
  • [20] Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients
    Penson, MG
    Winter, WE
    Fricker, FJ
    Harker, K
    Kahler, DA
    Kubilis, PS
    Schowengerdt, KO
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1999, 18 (07) : 707 - 713